NGM282: Additional Ph II data

Additional data from a double-blind, international Phase II trial in 82 NASH patients with stage 1-3 liver fibrosis and ≥8% liver fat content showed that once-daily 3 and 6 mg subcutaneous NGM282 for 12 weeks led to a ≥5% reduction in absolute liver fat content as measured by MRI-PDFF, the primary endpoint, in 74% and 85% of patients, respectively, vs. 7% of patients receiving placebo (p<0.001 for both). Low- and high-dose NGM282 increased LDL-C by 52 and 38 mg/dL, respectively. NGM said that preliminary data from an ongoing study in NASH patients suggests that statin therapy can reverse NGM282-associated elevations in LDL levels...